Filed with NSE · · 3 pages · English
Glenmark Pharmaceuticals Inc., USA has launched Vancomycin Hydrochloride for Injection in various single-dose vial strengths. This product is bioequivalent and therapeutically equivalent to a reference drug from Mylan Laboratories Limited. The announcement highlights Glenmark's commitment to expanding its institutional portfolio with quality products. The filing serves as a press release to inform stakeholders about this new product launch.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated April 01, 2025, titled "Glenmark Pharmaceuticals Inc., USA launches Vancomycin Hydrochloride for Injection USP, 750mg/vial, 1.25 g/vial and 1.5 g/vial (Single-Dose Vial)".
Glenmark Pharmaceuticals Limited on 6ix
Follow Glenmark Pharmaceuticals into a list and get an email when it puts out news.
Follow Glenmark Pharmaceuticals